Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway.

Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A, Parrini MC, Mazières J, Vaisse-Lesteven M, Camonis J, Levallet G, Zalcman G.

Cancer Res. 2016 Mar 15;76(6):1627-40. doi: 10.1158/0008-5472.CAN-15-1008. Epub 2016 Jan 12.

2.

RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.

Bousquet E, Calvayrac O, Mazières J, Lajoie-Mazenc I, Boubekeur N, Favre G, Pradines A.

Oncogene. 2016 Apr 7;35(14):1760-9. doi: 10.1038/onc.2015.240. Epub 2015 Jul 6.

PMID:
26148238
3.

Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.

Vlahov N, Scrace S, Soto MS, Grawenda AM, Bradley L, Pankova D, Papaspyropoulos A, Yee KS, Buffa F, Goding CR, Timpson P, Sibson N, O'Neill E.

Curr Biol. 2015 Dec 7;25(23):3019-34. doi: 10.1016/j.cub.2015.09.072. Epub 2015 Nov 5.

4.

Repression of YAP by NCTD disrupts NSCLC progression.

Guo J, Wu Y, Yang L, Du J, Gong K, Chen W, Dai J, Li X, Xi S.

Oncotarget. 2017 Jan 10;8(2):2307-2319. doi: 10.18632/oncotarget.13668.

6.

Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.

Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD.

J Natl Cancer Inst. 2001 May 2;93(9):691-9.

7.

TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.

Pefani DE, Pankova D, Abraham AG, Grawenda AM, Vlahov N, Scrace S, O' Neill E.

Mol Cell. 2016 Jul 7;63(1):156-66. doi: 10.1016/j.molcel.2016.05.012. Epub 2016 Jun 9.

8.

RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.

Calvayrac O, Pradines A, Favre G.

Small GTPases. 2018 Jul 4;9(4):339-344. doi: 10.1080/21541248.2016.1234429. Epub 2016 Nov 1. Review.

9.

Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.

Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F.

Oncogene. 2001 Mar 22;20(12):1509-18.

10.

RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.

Sato N, Fukui T, Taniguchi T, Yokoyama T, Kondo M, Nagasaka T, Goto Y, Gao W, Ueda Y, Yokoi K, Minna JD, Osada H, Kondo Y, Sekido Y.

Int J Cancer. 2007 Feb 1;120(3):543-51.

11.

Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.

Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T, Nakajima T, Nakagawara A, Kimura H.

Oncol Rep. 2006 May;15(5):1281-5.

PMID:
16596198
12.

[Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].

Zhang H, Zhang S, Zhang Z, Jia H, Gu S, Zhao D.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):311-6. doi: 10.3779/j.issn.1009-3419.2010.04.08. Chinese.

13.
14.

RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.

Ahn EY, Kim JS, Kim GJ, Park YN.

Mol Cancer Res. 2013 Jul;11(7):748-58. doi: 10.1158/1541-7786.MCR-12-0665. Epub 2013 Apr 17.

15.

Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.

Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER.

Cancer Res. 2001 Oct 1;61(19):7277-81.

16.

RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.

Choi N, Son DS, Song I, Lee HS, Lim YS, Song MS, Lim DS, Lee J, Kim H, Kim J.

Int J Cancer. 2005 Jul 1;115(4):575-81.

17.

Epigenetic regulation of RhoB loss of expression in lung cancer.

Mazières J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C, Pradines A, Jablons D, Favre G.

BMC Cancer. 2007 Nov 30;7:220.

18.

Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.

Pastuszak-Lewandoska D, Kordiak J, Migdalska-Sęk M, Czarnecka KH, Antczak A, Górski P, Nawrot E, Kiszałkiewicz JM, Domańska D, Brzeziańska-Lasota E.

Respir Res. 2015 Jun 26;16:76. doi: 10.1186/s12931-015-0230-6.

19.

Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer.

Watanabe K, Amano Y, Ishikawa R, Sunohara M, Kage H, Ichinose J, Sano A, Nakajima J, Fukayama M, Yatomi Y, Nagase T, Ohishi N, Takai D.

Cancer Med. 2015 Oct;4(10):1573-82. doi: 10.1002/cam4.505. Epub 2015 Aug 8.

20.

Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.

Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER, Latif F.

Oncogene. 2003 Jan 9;22(1):147-50.

PMID:
12527916

Supplemental Content

Support Center